Indivior Plc (Indivior) develops and markets medicines for the treatment of opioid addiction. The company offers suboxone a monthly depot, and only approved film treatment for opioid dependence; subutex, a mono-buprenorphine sublingual tablet, sublocad injection, and nalscue for opioid use disorder; and perseris for schizophrenia. Its pipeline portfolio encompasses buprenorphine-based products, including INDV-1000 in pre-clinical phase and INDV-2000 in Phase I for substance use disorder; and AEF0117 in Phase II for treatment of cannabis disorder. Indivior offers products in the form of film, tablets, and subutex tabs. It offers its products in the US, Australia, Malaysia, France, Italy, Spain, Germany, Canada, and the UK. Indivior is headquartered in Slough, the UK.

Headquarters United Kingdom

Address 234 Bath Road, Slough, SL14EE


Telephone 44 1753 217800

No of Employees 802

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange INDV (LON)

Revenue (2020) $791.0M 22.3% (2020 vs 2019)

EPS XXX

Net Income (2020) XXX 238.5% (2020 vs 2019)

Market Cap* $2.2B

Net Profit Margin (2020) XXX 213.3% (2020 vs 2019)

* As of and is in US$

Access premium data and analytics for Indivior Plc

60+

Clinical Trials

Determine Indivior Plc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

20+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Indivior Plc’s relevant decision makers and contact details.

20+

Catalyst Calendar

Proactively evaluate Indivior Plc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

18+

Marketed Drugs

Understand Indivior Plc’s commercialized product portfolio to stay one step ahead of the market.

14+

Pipeline Drugs

Identify which of Indivior Plc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

5

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

4

Sales & Consensus Forecasts

Understand the current and future drug revenue for Indivior Plc and assess market opportunity for new entrants with patient population 8-year forecasts.

3

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

4

Medical Clinical Trials

A database of clinical trials planned, currently ongoing, completed, suspended, withdrawn, and terminated in countries around the world.

3

Medical Marketed Products

A database of medical devices currently for sale around the world. Devices that have been approved by a regulatory authority are included.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Indivior Plc’s likely spend across technology areas enabling you to understand the digital strategy.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products Brands
Opiod Dependence Drugs: Subutex
Suboxone (Sublingual Film/Sublingual Tablet) Suboxone
Subutex (Sublingual Tablet) Sublocade
XXX XXX
XXX XXX
XXX XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 Others In July, the company purchased 149,015 shares.
2021 Others In December, the company purchased 256,055 own shares.
2021 Contracts/Agreements In June, the company and Aelis Farma entered into a collaboration and option-license agreement for the treatment of cannabis-related disorders.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Indivior Plc AstraZeneca Plc GW Pharmaceuticals Ltd Martindale Pharmaceuticals Ltd Vernalis R&D Ltd
Headquarters United Kingdom United Kingdom United Kingdom United Kingdom United Kingdom
City Slough Cambridge Cambridge Buckinghamshire Cambridge
State/Province - Cambridgeshire Cambridgeshire Buckinghamshire Cambridgeshire
No. of Employees 802 83,100 - - -
Entity Type Public Public Private Private Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Graham Hetherington Chairman Executive Board 2020 -
Mark Crossley Chief Executive Officer; Director Executive Board 2020 -
Ryan Preblick Director; Chief Financial Officer Executive Board 2020 -
Jeffrey Burris Chief Legal Officer Senior Management 2021 -
Cynthia Cetani Chief Integrity Officer; Chief Compliance Officer Senior Management 2018 -
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer